The Medical Center of Delaware (MCD) CCOP Program has been organized to facilitate participation by community physicians in the Delaware region in CALGB, NSABP & CCG clinical trials. The CCOP will utilize the comprehensive diagnostic and therapeutic facilities of the MCD and its affiliated hospitals. The participating oncologists and hematologists who utilize these institutions have expertise in all modalities of cancer care. The MCD has long standing relationships with its research bases and has participated in patient accrual since 1966. The MCD CCOP has an extensive catchment area which includes all Delaware and portions of Cecil County, MD, Salem County, NJ and Chester, Montgomery, and Delaware Counties in PA. This represents a patient population base in excess of 1.5 million with very large protocol entry potential.
The specific aim of this grant request is to continue our CCOP so that we can maintain state- of-the-art cancer care in our community with a strong commitment to cancer control research. Our accrual has continued to increase over the last 3 years of CCOPIII, compared to 1986 (pre-CCOP). With grant funding we anticipate this to continue with even greater increases in cancer control activities. This CCOP has shown growth in both treatment and cancer control research accrual, and expects substantial growth through its new affiliations and participation in both the BCPT and PCPT can control studies. We will continue our commitment to scientific protocol development as shown by our membership and participation in Core Committees of CALGB, NSABP and CCG. The CCOP administration will consist of the principal investigators, project coordinators, and data managers. This administration will distribute data to participating investigators as well as maintain and monitor quality control. Patient information is forwarded from the individual practices to the CCOP main office where flow sheets are completed and sent to the research bases for appropriate data analysis and statistical support. Data distribution and attendance at the semiannual research base meetings will be used as mechanisms for further education, allowing dissemination of protocol information and research concepts. The overall impact of this grant will be to assure continuation and stimulate expansion of CCOP activities at the MCD and its affiliates. This mechanism will also allow for participation in cancer control research throughout the region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045418-12
Application #
2712611
Study Section
Special Emphasis Panel (SRC (74))
Program Officer
Dunn, Barbara K
Project Start
1987-08-05
Project End
1999-05-31
Budget Start
1998-07-20
Budget End
1999-05-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Christiana Care Health Services, Inc.
Department
Type
DUNS #
City
Newark
State
DE
Country
United States
Zip Code
19713
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7

Showing the most recent 10 out of 100 publications